{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:19:04Z","timestamp":1744431544245,"version":"3.40.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.urolonc.2024.10.010","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:17:40Z","timestamp":1730395060000},"page":"195.e21-195.e27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline genetic testing for prostate cancer: Ordering trends in the era of expanded hereditary cancer screening recommendations"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7746-7633","authenticated-orcid":false,"given":"Jacob L.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke Luchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler M.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Madlensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Salmasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Karim","family":"Kader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Javier-Desloges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3358-1193","authenticated-orcid":false,"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.10.010_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0003","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jnci\/djaa132","article-title":"Germline sequencing DNA repair genes in 5545 men with aggressive and nonaggressive prostate cancer","volume":"113","author":"Darst","year":"2020","journal-title":"JNCI J Natl. Cancer Inst"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2022.12.021","article-title":"Genetic risk prediction for prostate cancer: implications for early detection and prevention","volume":"83","author":"Seibert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomized, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0006","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer (Version 1.2023). \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed July 7th, 2023. To view the most recent and complete version of the guideline, go online to https:\/\/NCCN.org."},{"key":"10.1016\/j.urolonc.2024.10.010_bib0007","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0008","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: philadelphia prostate cancer consensus conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0009","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1200\/OP.22.00638","article-title":"Implementation of a telehealth genetic testing station to deliver germline testing for men with prostate cancer","volume":"19","author":"Kwon","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0010","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1186\/s12885-022-10429-2","article-title":"Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study","volume":"22","author":"Vlaming","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0011","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JU.0000000000003186","article-title":"Clinical impact of a rapid genetic testing model for advanced prostate cancer patients","volume":"209","author":"Breen","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0012","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40200-021-00880-6","article-title":"Genomic medicine on the frontier of precision medicine","volume":"21","author":"Hasanzad","year":"2021","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0013","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2017.74.7899","article-title":"Genetic testing: what problem are we trying to solve?","volume":"35","author":"Hughes","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0014","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","article-title":"Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017","volume":"36","author":"Giri","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/CCI.20.00134","article-title":"Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors","volume":"4","author":"Patt","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0016","unstructured":"Mehrotra, A., Chernew, M., Linetsky, D., Hatch, H., Cutler, D., Schneider, E., 2021. The impact of COVID-19 on outpatient visits in 2020: visits remained stable, despite a late surge in cases. https:\/\/www.commonwealthfund.org\/publications\/2021\/feb\/impact-covid-19-outpatient-visits-2020-visits-stable-despite-late-surge, doi:10.26099\/bvhf-e411."},{"key":"10.1016\/j.urolonc.2024.10.010_bib0017","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/10781552221094308","article-title":"Rucaparib and olaparib for the treatment of prostate cancer: a clinician's guide to choice of therapy","volume":"28","author":"Keisner","year":"2022","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol. Pharm. Pract"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0018","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/cancers14041059","article-title":"The feasibility of implementing mainstream germline genetic testing in routine cancer care\u2014a systematic review","volume":"14","author":"Bokkers","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0019","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/pros.24480","article-title":"Utilization of genetic testing in men with advanced prostate cancer","volume":"83","author":"Aguiar","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0020","article-title":"Practice patterns and adherence to society guidelines for suspected choledocholithiasis: A comparison of academic and community settings from a large US healthcare system","volume":"9","author":"Rashtak","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.010_bib0021","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1200\/OP.22.00634","article-title":"Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review","volume":"19","author":"Briggs","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0022","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41391-021-00469-3","article-title":"Disparities in germline testing among racial minorities with prostate cancer","volume":"25","author":"Weise","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0023","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41391-022-00517-6","article-title":"Germline alterations among Hispanic men with prostate cancer","volume":"25","author":"Pan","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0024","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clgc.2019.04.013","article-title":"Germline genetic testing in advanced prostate cancer - practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium","volume":"17","author":"Paller","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0025","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.18.02181","article-title":"Germline testing for men with prostate cancer: navigating an expanding new world of genetic evaluation for precision therapy and precision management","volume":"37","author":"Giri","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2024.10.010_bib0026","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.euf.2022.03.018","article-title":"What is a variant of uncertain significance in genetic testing?","volume":"8","author":"Nicolosi","year":"2022","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:39:02Z","timestamp":1744414742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1078143924006902"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline genetic testing for prostate cancer: Ordering trends in the era of expanded hereditary cancer screening recommendations","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}